Abstract Background The overall 5-year survival rate of lung cancer is about 15% even with therapeutic drugs like tyrosine kinase inhibitors. Ideal models are urgently needed for exploring mechanisms and finding new drugs. Patient-derived xenografts (PDX) models and primary cells are both used to screen therapeutic regimens for cancer. However, PDX models and primary cells from the same patient are difficult to establish. Their consistency to the original tumor tissue is not well studied. Methods 31 lung cancer patient tissues were procured to establish the lung cancer PDX models and primary cell lines. Tumor growth measurements, histological and immunohistochemistry analysis, Western blotting, EGFR and K-RAS mutation detection and gefitini...
International audiencePreclinical lung cancer models are essential for a basic understanding of lung...
New approaches to optimization of cancer drug development in the laboratory and the clinic will be r...
Objective: Recent trials have evaluated adjuvant chemotherapy in patients with non-small-cell lung c...
Background and objective With the ongoing need to improve therapy for lung cancer, there has been an...
With the development of tumor molecular biology and genomics, it has been recognized that there are ...
BACKGROUND: Preclinical models that can better predict therapeutic activity in clinical trials are...
Patient-derived xenograft (PDX) models are an effective preclinical in vivo platform for testing the...
<div><p>Patient-derived xenograft (PDX) models generated from surgical specimens are gaining popular...
PURPOSE: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (...
Background: At present, there are two main types of lung cancer xenograft models: those derived from...
<div><p>Small cell lung cancer (SCLC) is a devastating disease with limited treatment options. Due t...
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. The high mortalit...
Lung cancer, which remains a major cause of mortality worldwide, is a histologically diverse conditi...
Abstract Background Patient-derived xenograft (PDX) models are important tools in precision medicine...
Background: The immune checkpoint of programmed cell death ligand 1 (PD-L1) commonly expressed in so...
International audiencePreclinical lung cancer models are essential for a basic understanding of lung...
New approaches to optimization of cancer drug development in the laboratory and the clinic will be r...
Objective: Recent trials have evaluated adjuvant chemotherapy in patients with non-small-cell lung c...
Background and objective With the ongoing need to improve therapy for lung cancer, there has been an...
With the development of tumor molecular biology and genomics, it has been recognized that there are ...
BACKGROUND: Preclinical models that can better predict therapeutic activity in clinical trials are...
Patient-derived xenograft (PDX) models are an effective preclinical in vivo platform for testing the...
<div><p>Patient-derived xenograft (PDX) models generated from surgical specimens are gaining popular...
PURPOSE: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (...
Background: At present, there are two main types of lung cancer xenograft models: those derived from...
<div><p>Small cell lung cancer (SCLC) is a devastating disease with limited treatment options. Due t...
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. The high mortalit...
Lung cancer, which remains a major cause of mortality worldwide, is a histologically diverse conditi...
Abstract Background Patient-derived xenograft (PDX) models are important tools in precision medicine...
Background: The immune checkpoint of programmed cell death ligand 1 (PD-L1) commonly expressed in so...
International audiencePreclinical lung cancer models are essential for a basic understanding of lung...
New approaches to optimization of cancer drug development in the laboratory and the clinic will be r...
Objective: Recent trials have evaluated adjuvant chemotherapy in patients with non-small-cell lung c...